Europe - Frankfurt Stock Exchange - FRA:LO3 - CH0013841017 - Common Stock
The current stock price of LO3.DE is 604.2 EUR. In the past month the price increased by 3.42%.
ChartMill assigns a technical rating of 5 / 10 to LO3.DE.
ChartMill assigns a fundamental rating of 4 / 10 to LO3.DE. LO3.DE has an average financial health and profitability rating.
Over the last trailing twelve months LO3.DE reported a non-GAAP Earnings per Share(EPS) of 16.64. The EPS increased by 16.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.33% | ||
| ROA | 3.9% | ||
| ROE | 8.5% | ||
| Debt/Equity | 0.49 |
30 analysts have analysed LO3.DE and the average price target is 743.91 EUR. This implies a price increase of 23.12% is expected in the next year compared to the current price of 604.2.
For the next year, analysts expect an EPS growth of 11.82% and a revenue growth 14.34% for LO3.DE
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| DIM.PA | SARTORIUS STEDIM BIOTECH | 49.49 | 20.76B | ||
| 56S1.DE | SARTORIUS STEDIM BIOTECH | 48.75 | 20.45B | ||
| SRT3.DE | SARTORIUS AG-VORZUG | 57.08 | 19.49B | ||
| SRT.DE | SARTORIUS AG | 43.86 | 14.98B | ||
| QIA.DE | QIAGEN N.V. | 20.09 | 8.89B | ||
| 1SXP.DE | SCHOTT PHARMA AG& CO KGAA | 15.44 | 2.26B | ||
| EVT.DE | EVOTEC SE | N/A | 2.24B | ||
| GXI.DE | GERRESHEIMER AG | 6.87 | 875.93M | ||
| FF.MI | FINE FOODS & PHARMACEUTICALS | 11.08 | 217.51M | ||
| 1SRT.MI | SARTORIUS AG | N/A | 15.35B | ||
| MLC.I | MALIN CORP PLC | N/A | 34.64M |
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. The company is headquartered in Basel, Basel-Stadt and currently employs 19,299 full-time employees. The company went IPO on 2002-04-03. The firm's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The firm divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
LONZA GROUP AG-REG
Muenchensteinerstrasse 38
Basel BASEL-STADT CH
Employees: 19299
Phone: 41613168111
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. The company is headquartered in Basel, Basel-Stadt and currently employs 19,299 full-time employees. The company went IPO on 2002-04-03. The firm's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The firm divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
The current stock price of LO3.DE is 604.2 EUR. The price increased by 0.3% in the last trading session.
LONZA GROUP AG-REG (LO3.DE) has a dividend yield of 0.72%. The yearly dividend amount is currently 4.29.
LO3.DE has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LO3.DE.
LONZA GROUP AG-REG (LO3.DE) will report earnings on 2026-01-28, after the market close.